Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic

Rituximab is a mouse/human chimeric monoclonal antibody targeted toward CD20. It is efficient as first-line therapy of CD20-positive B-cell malignancies. However, a large fraction of treated patients relapse with rituximab-resistant disease. So far, only modest progress has been made in treatment op...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Maximilian, Yumul, Roma, Saydaminova, Kamola, Wang, Hongjie, Gough, Michael, Baldessari, Audrey, Cattaneo, Roberto, Lee, Frank, Wang, Chung-Huei Katherine, Jang, Haishan, Astier, Anne, Gopal, Ajay, Carter, Darrick, Lieber, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813608/
https://www.ncbi.nlm.nih.gov/pubmed/27069950
http://dx.doi.org/10.1038/mtm.2016.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813608/
https://www.ncbi.nlm.nih.gov/pubmed/27069950
http://dx.doi.org/10.1038/mtm.2016.13

Ejemplares similares